<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03130621</url>
  </required_header>
  <id_info>
    <org_study_id>CGOG1012</org_study_id>
    <nct_id>NCT03130621</nct_id>
  </id_info>
  <brief_title>Screening of Hereditary Upper Gastrointestinal Cancer in China</brief_title>
  <official_title>Screening of Hereditary Upper Gastrointestinal Cancer in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Through exploring the specific genetic mutations in the upper gastrointestinal tract tumors
      with a family history and specific clinical pathological types，we establish a complete family
      and follow-up system，in order to improve the screening criteria of Chinese hereditary upper
      gastrointestinal tumors and carry on primary prevention of disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pedigree analysis</measure>
    <time_frame>In the first phase of the project, we plan to detect 40-50 families in one year.</time_frame>
    <description>We plan to analyse the families of patients who met the inclusion criterias through gene detection.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Improve the Screening Criteria of Chinese Hereditary Upper Gastrointestinal Tumors</condition>
  <arm_group>
    <arm_group_label>Adenocarcinoma of upper digestive tract</arm_group_label>
    <description>Early-onset carcinomas ; Family History of Malignancy; Special pathological type; MSI or dMMR; Multiple primary malignant tumors;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esophageal squamous cell carcinoma</arm_group_label>
    <description>Family History of Malignancy; Multiple primary malignant tumors; MSI or dMMR;</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Gene detection</intervention_name>
    <description>Next-generation sequencing</description>
    <arm_group_label>Adenocarcinoma of upper digestive tract</arm_group_label>
    <arm_group_label>Esophageal squamous cell carcinoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Upper Gastrointestinal Cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with gastric cancer, esophageal adenocarcinoma, or duodenal adenocarcinoma meet
        one of the following criteria:

          1. age≤30;

          2. age≤35，gastric cancer with special pathological types;

          3. age≤50，≥one first-degree relative of a malignant tumor;

          4. ≥ two first-degree／second-degree relatives of a malignant tumor，and ≥one first-degree
             relative;

          5. have ≥two types of malignancies，and age ≤50 at the first time of diagnosis;

          6. MSI or dMMR of tissue specimen;

        Patients with esophageal squamous cell carcinomas meet one of the following criteria:

          1. ≥ two first-degree／second-degree relatives of a malignant tumor，and ≥one first-degree
             relative;

          2. have ≥two types of malignancies，and age ≤50 at the first time of diagnosis;

          3. MSI or dMMR of tissue specimen;

        Exclusion Criteria:

          -  Patients do not meet one of the inclusion criteria;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shen Lin, Professor</last_name>
      <phone>010-88196561</phone>
      <email>Linshenpku@163.com</email>
    </contact>
    <investigator>
      <last_name>Shen Lin, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2017</study_first_submitted>
  <study_first_submitted_qc>April 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2017</study_first_posted>
  <last_update_submitted>April 22, 2017</last_update_submitted>
  <last_update_submitted_qc>April 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>Chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

